Geospatial patterns in human papillomavirus vaccination uptake: Evidence from uninsured and publicly insured children in North Carolina

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 3, 2015, Pages 595-602

  Trogdon, Justin G ^a   Ahn, Thomas ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; FEMALE; GEOGRAPHIC AND GEOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; UNITED STATES; VACCINATION; ZIP CODE TABULATION AREA; ADULT; EPIDEMIOLOGY; GEOGRAPHY; PAPILLOMAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; FEMALE; GEOGRAPHY; HUMANS; MALE; MEDICALLY UNINSURED; NORTH CAROLINA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 84927764131     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1231     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013;62:591-5.
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
3. Centers for Disease Control and Prevention. Recommendationson the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.
4. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-93.
5. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.
6. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:308-20.
7. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manage Care Pharm 2010;16:217-30.
8. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011;29:8443-50.
9. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wrkly Rep 2013;62:685-93.
10. Moss JL, Gilkey MB, Reiter PL, Brewer NT. Trends in HPV vaccine initiation among adolescent females in North Carolina, 2008-2010. Cancer Epidemiol Biomarkers Prev 2012;21:1913-22.
11. Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M. Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol 2013;42: 896-908.
12. Tsui J, Gee GC, Rodriguez HP, Kominski GF, Glenn BA, Singhal R, et al. Exploring the role of neighborhood socio-demographic factors on HPV vaccine initiation among low-income, ethnic minority girls. J Immigr Minor Health 2013;15:732-40.
13. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 2007;110:87-95.
14. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014;168:76-82.
15. Reiter PL, Cates JR, McRee AL, Gottlieb SL, Shafer A, Smith JS, et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis 2010;37:549-56.
16. Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med 2010;38:525-33.
17. Moss JL, Gilkey MB, Griffith T, Bowling JM, Dayton AM, Grimshaw AH, et al. Organizational correlates of adolescent immunization: findings of a state-wide study of primary care clinics in North Carolina. Vaccine 2013;31:4436-41.
18. Rondy M, van Lier A, vande Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 2010;28:2070-5.
19. Nelson EJ, Hughes J, Kulasingam SL. Spatial patterns of human papillomavirus-associated cancers within the state of Minnesota, 1998-2007. Spat Spatiotemporal Epidemiol 2014;9:13-21.
20. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG. U.S. geographic distribution ofprevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev 2011;20:591-9.
21. Tsui J, Rodriguez HP, Gee GC, Escobedo LA, Kominski GF, Bastani R. Are HPV vaccination services accessible to high-risk communities? A spatial analysis of HPV-associated cancer and Chlamydia rates and safety-net clinics. Cancer Causes Control 2013;24:2089-98.
22. Reiter PL, Katz ML, Paskett ED. HPV vaccination among adolescent females from Appalachia: implications for cervical cancer disparities. Cancer Epidemiol Biomarkers Prev 2012;21:2220-30.
23. Dayton A. Improving quality of health care using the North Carolina Immunization Registry. North Carolina Med J 2014;75:198-203.
24. Centers for Disease Control and Prevention. Vaccines for Children Program (VFC) [updated April 24, 2014]. Available from: http://www.cdc.gov/vaccines/programs/vfc/index.html.
25. Health Landscape. ZIP Code to ZCTA Crosswalk [updated May 16, 2014]. Available from: www.udsmapper.org/zcta-crosswalk.cfm.
26. U.S. Census Bureau. TIGER Products [updated May 16, 2014]. Available from: https://www.census.gov/geo/maps-data/data/tiger.html.
27. Moran PAP. Notes on Continuous Stochastic Phenomena. Biometrika 1950;37:17-23.
28. Neyens T, Faes C, Molenberghs G. A generalized Poisson-gamma model for spatially overdispersed data. Spat Spatiotemporal Epidemiol 2012;3: 185-94.
29. Brien S, Kwong JC, Charland KM, Verma AD, Brownstein JS, Buckeridge DL. Neighborhood determinants of 2009 pandemic A/H1N1 influenza vaccination in Montreal, Quebec, Canada. Am J Epidemiol 2012;176: 897-908.
30. Centers for Disease Control and Prevention. Interim results: state-specific seasonal influenza vaccination coverage - United States, August 2009-January 2010. MMWR Morb Mortal Wrkly Rep 2010;59: 477-84.
31. Grubesic TH, Matisziw TC. On the use of ZIP codes and ZIP code tabulation areas (ZCTAs) for the spatial analysis of epidemiological data. Int J Health Geogr 2006;5:58.
32. Best N, Richardson S, Thomson A. A comparison of Bayesian spatial models for disease mapping. Stat Methods Med Res 2005;14:35-59.
33. Wakefield J. Disease mapping and spatial regression with count data. Biostatistics 2007;8:158-83.
34. Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Sources and perceived credibility of vaccine-safety information for parents. Pediatrics 2011;127:S107-12.
35. Wu B, Fu F, Wang L. Imperfect vaccine aggravates the long-standing dilemma of voluntary vaccination. PLoS ONE 2011;6:e20577.